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BACKGROUND: Small intestinal neuroendocrine neoplasm (SI-NEN) proliferation is quantified by Ki67
measurements which capture G1-G2M phases of the cell cycle. G0 and early G1 phases, typical of slow-
growing cells, can be detected by minichromosome maintenance protein (MCM) expression. We hypothesized
that these replication licensing markers may provide clinically relevant information to augment Ki67 in low-grade
neuroendocrine neoplasia. METHODS: Immunohistochemical staining (IHC), Western blot analysis, quantitative
polymerase chain reaction, and copy number variations of MCM2, MCM3, and Ki67 were undertaken in SI-NENs
(n = 22). MCM and Ki67 expression was compared by Kaplan-Meier survival analysis (tissue microarray,
independent set [n = 55]). Forty-three pancreatic NENs and 14 normal tissues were included as controls.
RESULTS: In SI-NENs, MCM2 (mean: 21.2%: range: 16%-25%) and MCM3 (28.7%: 22%-34%) were detected in
significantly more cells than Ki67 (2.3%: 0%-7%, P b .01). MCM2 mRNA correlated with Ki67 IHC (P b .05). MCM3
protein expression was higher in metastases (38-fold) than in normal small intestine (P = .06) and was largely
absent in normal neuroendocrine cells. There was considerable variation at the MCM copy number level (0-4
copies). MCM3 expression in proliferating cells significantly predicted overall survival (P b .002). Combinations of
Ki67 and MCM2/3 in algorithms differentiated low and higher proliferative lesions (overall survival: 12 vs 6.1 years,
P = .06). MCM expression was not informative in pancreatic NENs. CONCLUSION: MCMs are expressed in a
higher proportion of NEN cells than Ki67 in slow-growing small intestinal lesions and correlate with survival.
Assessment can be used to augment Ki67 to improve prognostic classification in these low-grade tumors.
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Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are
increasing in incidence and prevalence [1] and exhibit significant
heterogeneity in outcome, so prognostic tools are of critical
importance. Currently, the most useful prognostic clinicopathological
variable is tumor cell proliferation. Assessment of proliferative indices
is well accepted and forms the basis for the current grading
classification [2]. The Ki67% is prognostic for survival in pancreatic
NENs [3,4] and has value in SI-NENs [2,5]. Although the index can
predict disease progression in the latter [6], G1 and G2 grading is not
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proportion of cells that are “positive” is low in both measures, i.e., the
lowest-grade NET G1 is defined by b2 mitosis per 10 high-powered
fields or ≤2% Ki67-positive cells per 2000 tumor cells [2]. There is
consequently a loss of discriminative sensitivity at the lower end of the
index. The requirement to detect single positive cells in several
high-powered fields is difficult and can significantly alter grade
assessment, thereby influencing therapeutic strategy. Although digital
approaches to quantitating the Ki67 index are available and are
expected to play a role in the future [8], there remains a need to
identify proliferative markers that are expressed in a higher proportion
of cells. This will confer added accuracy to the grading of tumors with
a low proliferative index.
Minichromosome maintenance (MCM) proteins are proliferative
markers whose function has been well described [9,10]. MCMs (2, 3,
4, 5, 6, and 7) combine to form the MCM complex which has a
crucial role in the replication of DNA; it is required both for the
initiation of transcription forks at DNA replication origins and for the
maintenance of the transcription fork as the genome is duplicated [9].
Mitosis can only progress once the MCM complex is unbound, which
ensures that a single copy of DNA segregates into each daughter cell
[11]. MCMs have a second, related function; they assist in chromatin
unwinding at the replication forks prior to transcription due to their
inherent helicase activity [10]. These well-characterized functions
contrast with our understanding of Ki67 whose function remains
poorly known [12].
MCM expression has been examined as a prognostic [10] and
proliferative [13,14] marker in many epithelial malignancies and
compared to Ki67. Correlations between Ki67 and MCM using
immunohistochemistry (IHC) have been demonstrated for MCM2
in colorectal [15–17], lung [18], and esophageal cancers [19] as well
as in endocrine cancers such as adrenocortical [20] and thyroid
carcinoma [21]. MCM3 expression has been associated with Ki67 in
melanoma [22] and ovarian cancer [23]. These results support
MCMs as proliferative markers. MCM2/3 expression is prognostic
for survival in both renal carcinoma [24] and cutaneous T-cell
lymphomas [25].
We hypothesized that MCMs would be detectable in NENs and
provide prognostic information, particularly in slow-growing tumors.
We therefore examined MCM2 and MCM3 expression in
GEP-NENs and in normal neuroendocrine cells from which these
tumors are derived [26]. The aims were to determine, firstly, whether
expression was elevated in NENs compared to normal neuroendo-
crine cells and, secondly, whether this information was prognostic of
survival. In addition, we sought to compare its predictive values with
the current clinical standard, Ki67.
Material and Methods
All samples were collected with permission of the Ethics Committees
of Yale University School of Medicine (USA) and the University of
Heidelberg (Germany).
Small Intestinal NENs
Fresh frozen tumor tissue was collected from 22 SI NENs and
normal small intestinal mucosa (n = 14) for the assessment of MCM
mRNA, copy number, and protein expression (set 1). These included
13 primary tumors and 9 metastases and were graded as G1 (n = 16)
and G2 NETs (n = 6) [2]. Samples were predominantly Caucasians
(95%), with a similar gender distribution (M:F 12:10). The averageage at diagnosis was 53.2 years (range: 35-66). A tissue microarray
(TMA) including 55 SI-NENs (previously described in detail [27])
was included as an independent set (set 2) to quantify immunostain-
ing using the Automated Quantitative Analysis (AQUA) protocol
[27,28] and evaluate whether expression correlated with overall
survival (OS). Samples on the TMA were predominantly obtained
from Caucasians (84%), with an even gender distribution (M:F
27:28). The average age at diagnosis was 62.1 years (range: 40-89),
and the median follow-up was 6.9 years (range: 6 days to 26.3 years).
All tumors were grade 1 (Ki67 ≤ 2%).
Pancreatic NENs
The pancreatic NEN data set of fresh frozen tumor tissue (n = 43,
38 primaries, 5 metastases) has been described [29]. Samples were
predominantly female (65%); the average age at diagnosis was 59.1
years (range: 13-74). Tumors were nonfunctional (63%); one was
MEN-1 (insulinoma). Tumors were graded as G1 (n = 18), G2 (n =
23), and G3 (n = 3). These samples, as well as normal pancreatic
tissue (n = 10), were also evaluated for MCM expression (set 3).
RNA isolation and reverse transcription. Messenger RNA was
extracted and converted to cDNA from each tissue sample (set 1 and
set 3) as described [29] using TRIZOL (Invitrogen, Carlsbad, CA),
the RNeasy kit (Qiagen, Valencia, CA), and the High-Capacity
cDNA Archive Kit (Life Technologies, Carlsbad, CA). Quantitative
reverse transcriptase polymerase chain reaction (PCR) was performed
using Assays-on Demand and the ABI 7900 Sequence Detection
System (Life Technologies). Primer sets (MCM2: Hs01091564_m1,
MCM3: Hs00172459_m1, Ki67: Hs00267195_m1) were obtained
from Life Technologies. PCR data were normalized using the ΔΔCT
method; ALG9 was used as a housekeeping gene [30].
Copy number variation (CNV) analysis. Genomic DNA was
isolated as described [31] from set 1 and set 3. CNV was measured
using PCR-Taqman Copy Number Reference Assay from Life
Technologies according to the manufacturer's instructions using the
primer sets Hs00575269_cn and Hs02422238_cn (MCM2) and
Hs00378664_cn (MCM3). CNVs of each gene were normalized to
telomerase reverse transcriptase. The results were analyzed with
CopyCaller v2.0 software (www.appliedbiosystems.com).
Immunostaining. This was performed as described [27,31] using
a 1:100 dilution of rabbit anti-MCM2 or -MCM3 (#4007 and 4102;
Cell Signaling Technology, Beverly, MA), anti-Ki67 (ab15580;
Abcam, Cambridge, MA), and anti–chromogranin A (A0430;
DAKO, Glostrup, Denmark) antibodies in set 2. The TMA was
examined by AQUA after immunofluorescent staining [32] and by a
pathologist (B. K.) after DAB staining (blinded to tissue labels). For
automated analysis, neuroendocrine tumor cells or normal mucosal
epithelia were identified using a fluorescently tagged mouse
anti-cytokeratin antibody cocktail (AE1/AE3; DAKO), nuclei were
visualized by 4′,6-diamidino-2-phenylindole, and targets were
visualized with a fluorescent chromogen (Cy-5-tyramide; NEN Life
Science Products, Boston, MA). AQUA expression values were
quantified as low (below median) or high expression (above median).
Protein extraction and western blot analysis. Pieces of tissue (1 × 2
mm) (set 1 and set 3) were processed [29] using manual
homogenization with RIPA lysis buffer (Millipore, Temecula, CA),
BCA-based protein quantitation (Thermo Fisher Scientific, Rockford,
IL), denaturation, and separation of total protein lysates (15 μg) on
10% SDS-PAGE gels (Invitrogen, Carlsbad, CA). Membranes were
probed with anti-MCM2 and anti-MCM3 (antibodies as for IHC).
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MO). The optical density of the appropriately sized band was measured
using ImageJ software 1.47 (NIH, Bethesda, MD).
Statistical evaluation. All statistical analyses were performed
using Microsoft Excel and Prism 6.0 (GraphPad Software, San Diego,
CA) using nonparametric methods. Multiple group comparisons were
performed using the Kruskal-Wallis test followed by the Dunn post
hoc test where appropriate. Binary comparisons were made using a
two-tailed Mann-Whitney test. Correlations were undertaken using
Spearman correlation. Survival analysis was conducted by
Kaplan-Meier curves after grouping staining results by low and
high (cut points approximating the median were chosen to maximize
prognostication) normalized AQUA scores, and significance was
determined by the log-rank statistic using GraphPad Prism 6.0Figure 1. Protein expression of MCM2 and MCM3 in small
Immunohistochemistry (A): MCM2 and MCM3 were identified in cry
site of cells involved in renewing mucosa where the highest mitosis r
of crypts; these cells were not stained by MCM2 (red arrows). Dual
neuroendocrine cells to be MCM2 or MCM3 positive (yellow arrows).
MCM2 and MCM3, and expression of both proteins tended to be
overexpression was also identified by Western blot (B), especially f
MCM3: P = .06, MCM2: P = .15).DAPI: nuclei (blue), FITC: target ma
cells (yellow). PZ = proliferative zone. Mean ± SD.software (GraphPad Software Inc., La Jolla, CA). A P value of b .05
was designated as significant.Results
Protein Expression of MCM2 and MCM3 in Normal Mucosa
and SI NENs (Set 1)
MCM2 and 3 protein expression was assessed in normal small
intestinal mucosa using IHC (Figure 1A). Less than 2% of
neuroendocrine cells (visualized by dual staining with chromogranin
A) were MCM positive, identifying low replication potential (and
proliferation rates) of those cells. In normal epithelial cells, MCMs
were predominantly localized to the “proliferative zone” [33] of the
small intestinal crypts (Figure 1A). SI NENs tended to exhibit higherintestinal mucosa and SI-NENs (primaries and metastases).
pts associated with the proliferative zone (PZ) (inset) which is the
ates are expected. Additional cells were MCM3 positive at the base
staining with chromogranin A identified only a few (b2%) normal
Both primary tumor and metastasis exhibited nuclear expression of
higher in metastasis in comparison to the primary tumor. This
or MCM3, but this was not statistically significant (Kruskal-Wallis,
rker (green), Cy5: chromogranin A (red-white arrows), dual-stained
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(Figure 1B, MCM2: P = .15, MCM3: P = .06, Kruskal-Wallis test).
Clinical Relevance ofMCMmRNAExpression in SI-NENs (Set 1)
Levels of MCM mRNA were similar in primaries and metastases.
However, MCM mRNA showed lower expression in metastases than
in normal mucosa (Figure 2A, P b .05). As expected, higher-grade
tumors (G2) were associated with elevated Ki67 and MCM2 mRNA
expression (P b .05, Figure 2B) than low-grade tumors (G1). MCM3
was also elevated, but this did not reach significance (three-fold, P =
.26). A comparison between Ki67 staining and mRNA expression of
Ki67, MCM2, and MCM3 (Figure 2C) identified that the Ki67%, as
anticipated, was correlated with Ki67 mRNA in SI NENs (r = 0.48,
P b .05). The Ki67% was also correlated with MCM2 mRNA levels
(r = 0.44, P b .05), but there was no correlation with MCM3 mRNA
(Figure 2C). At an mRNA level, strong correlations were noted
between Ki67 and both MCMs (r = 0.53-0.6, P b .01). Analysis of
copy number identified that normal tissues exhibited two stable
copies of MCM2 and MCM3 genes, whereas SI NENs demonstrated
wide variation (0-4 copies) (Figure 2D). This variation in copy
number was not directly correlated with differences in mRNA or
protein expression, e.g., in the Western blot analyses (Figure 1B).Figure 2. Clinical relevance of MCM and Ki67 expression in SI-NENs.
neoplastic small intestinal tumors, whereas Ki67 was not significantly
(B) Ki67 and MCM2 expression was significantly increased (*P b .05) i
but this did not achieve statistical significance. (C) Correlation betwee
for MCM2 (r2 = 0.44, P b .05) but not for MCM3. Expression of either
r= 0.6, P= .0027, MCM3: r= 0.53, P= .0092) and with each other (r
three markers in both primary tumors and in metastases; this was nExpression and Correlation with Survival (Set 2)
We next evaluated Ki67 andMCM2/3 immunostaining to determine
the proportion of tumors that expressed each marker. An evaluation of
Ki67 staining identified that 25 (37%) of 55 samples were positive for
Ki67, with the remainder showing no Ki67-positive tumor cells in the
examined fields. In contrast, at least some MCM2 and 3 positivity was
identified in all lesions (χ2 38.55, P b .0001). Analysis of individual cell
counts identified significantly more MCM3-positive cells (mean: 28.7%
[range 22%-34%]) and MCM2-positive cells (mean 21.2% [range:
16%-25%]) than Ki67-positive cells (mean: 2.3%: [range 0%-7%, P b
.01]). This indicates that these markers identified a greater proportion of
tumor cells than Ki67 per se.
Thereafter, we examined whether MCM2 and 3 protein expression
was prognostic for survival in these lesions. Groups were prospectively
divided as below or above the median to represent low or high expression
of each protein. As demonstrated in Figure 3, the differences in median
OS between low- and high-expression groups were large for bothMCM2
(8.7-year difference) and MCM3 (5.3-year difference). The log-rank
statistic, however, did not reach significance (MCM2, hazard ratio [HR]
0.56, P = .15, Figure 3A; MCM3, HR 0.76, P = .49, Figure 3B). Like
MCMs, Ki67 also did not significantly prognosticate survival in this
cohort (HR 0.52, P = .14).(A) MCM expression in normal mucosa tended to be higher than in
different between any tissue type (*P b .05 versus normal mucosa).
n grade 2 compared to grade 1 tumors. MCM3 was also increased,
n MCMmRNA expression and Ki67 staining identified a relationship
MCM significantly correlated with Ki67 mRNA expression (MCM2:
= 0.69, P= .004). (D) High copy number variance was noted for all
ot seen in normal mucosa. Mean ± SD.
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NENs, we combined the results of Ki67 with MCM2 and 3 to
generate a proliferative marker score based on the number of elevated
markers in each tumor. In this algorithm, e.g., a tumor with high
levels of 2-3 markers but low levels of 0-1 markers would score “2-3”
out of a maximum of 3. Individuals with tumors with low
proliferation scores (0-1; n = 21) had prolonged survival (median
OS 11.98 years) compared to those with tumors exhibiting high
proliferative scores (2-3; n = 23; median OS 6.15 years) (log-rank P =
.06) (Figure 3C).
In the examination of the 25 tumors with detectable Ki67%, a high
MCM3 expression was associated with a worse prognosis (OS 3.8
years), whereas after more than 25 years of follow-up, the median OS
of patients with low MCM3 expression was not reached (Figure 3D,
P = .0019, HR 0.13).
MCM2 and MCM3 in Normal Pancreas and Pancreatic
NENs (Set 3)
As comparators, we examined MCM expression in pancreatic
NENs which generally exhibit a higher proliferative rate and are
known to be more aggressive [1]. Elevated mRNA expression of
MCM2 and MCM3 was identified in metastases compared to
primaries or normal pancreas, respectively (Figure 4A, Kruskal-Wallis
P b .0001, post hoc P b .05). Similar elevations of Ki67 mRNA wasFigure 3. Survival curves for AQUA analysis of MCM2 and MCM3 in
associated with notably longer OS. Using a combination of proliferat
21) had prolonged survival (median OS 12 years) compared to those w
6.5) (C, P= .06, HR 0.46). A high MCM3 expression was correlated w
the median OS of patients with low MCM3 expression was not reac
.019, HR 0.13).noted in metastases (Figure 4A, post hoc P b .05). Ki67 and MCM
expression correlated with tumor size (Ki67% r = 0.39, P b .05; Ki67
mRNA r = 0.41, P b .05; MCM2 r = 0.52, P b .01; and MCM3 r =
0.55, P b .01) but not with lymph node status or angioinvasion (data
not shown). MCM expression was not related to grade (Figure 4B).
Although MCM2 and MCM3 proteins were elevated in tumors, the
differences were not significant (Figure 4C).
Discussion
We examinedMCM2 andMCM3 expression in neuroendocrine cells
from the small intestine and pancreas and then evaluated their
potential role as proliferative and prognostic markers. This was
undertaken as the Ki67 index has limitations as a proliferative marker
in low proliferating tumors, particularly in those derived from the
small intestine [4,34].
Normal small intestinal neuroendocrine cells seldom exhibited
either MCM2 or MCM3 positivity, confirming that few cells are
replication licensed; the majority are terminally differentiated. In
addition, we could not identify MCM2 or 3 in a small intestinal
transcriptome library [35]; expression of mRNA was undetectable by
quantitative PCR in five of six small intestinal enterochromaffin cell
preparations (data not shown). SI-NENs are largely homogeneous
and exhibit a low proliferation (they are predominantly grade NET
G1) [36]. Despite this, MCM3 protein expression was higher inSI-NENs. Low expressions of MCM2 (A) and MCM3 (B) were both
ive markers, patients with low–proliferation score tumors (0-1; n =
ith high–proliferation scores tumors (2-3; n= 24) (median OS years
ith worst prognosis, whereas after more than 25-years of follow-up,
hed in the subset of tumors that were only Ki67% positive (D, P =
Figure 4.mRNA and protein expression of MCM2 andMCM3 in normal pancreas and pancreatic NENs (primaries andmetastases). (A) MCM2
andMCM3mRNAswere elevated inmetastases in comparison to normal pancreas and to primaries, whereas Ki67was elevated inmetastases
compared to normal pancreas (Kruskal-Wallis P b 0.0001, *P b .05 versus normal, #P b .05 versus primaries). (B) Ki67 and MCM mRNA
expression as a function of grade identified no significant differences in pancreatic NENs. (C) UsingWestern blot, an elevation of MCM protein
expression in pNEN metastases was confirmed (Kruskal-Wallis, MCM2: P = .24, MCM3: P = .44). Mean ± SD.
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MCM3: P = .06) identifying that tumor cells are replication licensed.
Although small intestinal mucosa may not be the perfect control
tissue due to low numbers of neuroendocrine cells (1%-2% of
mucosa), the observation that expression is increased in NENs
compared to a tissue resource that has a high turnover confirms our
hypothesis that MCM expression in NENs is of biological relevance.
The elevation in tumors is not likely to be due to changes in copy
number (Figure 2D). The significance of CNV noted is uncertain,
with possible explanations including chromosomal instability [37]
(albeit less commonly seen than in most cancer types) or
tumor-specific changes in the reference gene. It does, however, raise
the possibility of an oncogenic effect targeting MCM2/3 which
specifically contributes to tumorigenesis in SI-NENs.Ki67 is currently the proliferation marker of choice for
GEP-NENs, and its expression at a protein level (IHC: Ki67 index
or Ki67%) is used to grade these lesions [6]. We contrasted MCM2
and MCM3 expression with Ki67 in SI-NENs. MCM2 mRNA
expression was correlated with Ki67 staining, Ki67 mRNA
expression, and grade. Interestingly, significantly more small
intestinal tumor cells were immunostained with MCM2 and 3
antibodies than Ki67, indicating that measurement of these proteins
may identify more cells, particularly those that are replication
licensed. This is of importance for these lesions because discrimina-
tion with Ki67 is difficult when neoplasms have “low” proliferative
rates (G1 SI-NETs: b2%). This also suggests that these tumors are
not quiescent but do have the potential to grow and can enter the cell
cycle and progress to active proliferation [38].
Translational Oncology Vol. 9, No. 5, 2016 MCM expression in neuroendocrine neoplasms Schimmack et al. 417To explore the clinical relevance of these observations, we evaluated the
relationship between MCM protein expression and OS using an
AQUA-based immunohistochemistry protocol [27,31]. In this analysis,
in an independent set of SI-NENs, Ki67 expression when measured by
AQUA staining was not prognostic of survival (HR 0.52; P = .14).
However, the median survival of SI-NENs with elevatedMCM2was 5.2
years compared to 13.9 years in tumors with low levels of MCM2 (HR
0.56). The prognostic ability of Ki67 and MCMs was amplified when
they were included in an algorithm. Tumors with elevated expression of
the majority of markers (2-3 markers) had poor survival (median OS 6.1
years) compared to tumors with elevated expression in a minority of
markers (0-1 markers: median OS 12 years). MCM3 itself was not
prognostic as a single marker, but in patients with tumors with detectable
Ki67, MCM3 staining was prognostic for survival (P = .019, HR 0.13).
When considered together, the correlation between MCM expression
and Ki67 expression confirms that MCMs are a proliferative marker in
GEP-NENs, and the survival analysis identifies that theymeasure a similar
phenomenon. It is evident that elevations in multiple markers (MCM2/3
and Ki67) are consistent with a poorer prognosis and highlights the
importance of identifying all cells that may be proliferating or have the
potential (are replication licensed) for entering the proliferative cycle.
In pancreatic NENs, MCM expression was generally higher in
metastases than in primaries and higher in primaries than in normal
pancreas. Such a spectrum has been previously identified in the
adenoma-dysplasia-carcinoma sequence in the transitions to adreno-
cortical carcinoma [20], prostate carcinoma [39,40], colorectal
carcinoma [41], melanoma [42], anal carcinoma [43], and thyroid
malignancies [21]. This continuum in pancreatic NENs recapitulates the
variability in proliferation in these tumors (pNENs range across grades
NET G1, NET G2, NEC) [44]. Because MCM expression behaves
similar to Ki67 in pNENs but do not correlate with grade, MCMs does
not appear to add to Ki67 in these more aggressive neoplasms.
Conclusion
MCM2 andMCM3 are proliferativemarkers inGEP-NENs, andMCM
protein expression is elevated in SINENs relative both to normalmucosa,
a proliferating, MCM-positive control, as well as to normal cells (little to
no expression). In addition, an MCM “proliferative index” is prognostic
of survival. Augmentation of Ki67 with a marker that measures
replication licensing and is expressed in a larger proportion of cells
could improve prognostic reliability. Furthermore, evaluation of the
mechanisms that govern MCM2/3 regulation may provide insight into
the regulation of SI-NEN proliferation and metastases.
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